Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2009; 101(03): 601-603
DOI: 10.1160/TH08-07-0482
DOI: 10.1160/TH08-07-0482
Letters to the Editor
Relation between atrial fibrillatory rate and markers of inflammation and haemostasis in persistent human atrial fibrillation
Financial support: This study has been performed in and supported in part by the NordForsk network “;Electrocardiology in Atrial Fibrillation”. Drs. D. Husser and M. Stridh are supported by the Volkswagen Foundation, Germany. The CAPRAF main study was sponsored by the Regional Health Corporation of Eastern Norway, and the Medical Research Foundation, Asker and Bærum Hospital, Norway. AstraZeneca, Mölndal, Sweden provided the study medication, and AstraZeneca, Oslo, Norway, supported the study with a grant to cover for laboratory analyses.Further Information
Publication History
Received:
25 July 2008
Accepted after major revision:
14 January 2009
Publication Date:
24 November 2017 (online)
-
References
- 1 Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder?. Eur Heart J 2006; 27: 136-149.
- 2 Choudhury A, Lip GY. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol Haemost Thromb 2003; 33: 282-289.
- 3 Chung MK, Martin DO, Sprecher D. et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
- 4 Vene N, Mavri A, Kosmelj K. et al. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003; 90: 1163-1172.
- 5 Tveit A, Grundvold I, Olufsen M. et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007; 120: 85-91.
- 6 Stridh M, Sornmo L, Meurling CJ. et al. Characterization of atrial fibrillation using the surface ECG: time-dependent spectral properties. IEEE Trans Biomed Eng 2001; 48: 19-27.
- 7 Stridh M, Sornmo L. Spatiotemporal QRST cancellation techniques for analysis of atrial fibrillation. IEEE Trans Biomed Eng 2001; 48: 105-111.
- 8 Bollmann A, Husser D, Mainardi L. et al. Analysis of surface electrocardiograms in atrial fibrillation: techniques, research, and clinical applications. Europace 2006; 8: 911-926.
- 9 Bollmann A, Husser D, Stridh M. et al. Atrial fibrillatory rate and risk of left atrial thrombus in atrial fibrillation. Europace 2007; 9: 621-626.
- 10 Conway DS, Heeringa J, van der Kuip DA. et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke 2003; 34: 413-417.
- 11 Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.